AOD-9604 potential benefits and areas of research

The honest answer on AOD-9604's benefits is short: in rodents it reliably increased fat breakdown and reduced weight gain, but in humans it never demonstrated meaningful weight loss, and its developer stopped the obesity program after mid-stage trials missed their endpoints. AOD-9604 is a modified copy of the last section (amino acids 177–191, the C-terminus) of human growth hormone — the region thought to carry GH's fat-metabolizing activity without its growth-promoting effects. Everything attractive about the molecule comes from that design idea and from animal data; nothing sold today is supported by positive human weight-loss trials.

The preclinical record is real and worth stating precisely, because it is the entire basis of the marketing:

• In obese Zucker rats, 19 days of oral AOD-9604 (500 mcg/kg daily) cut body-weight gain by more than half versus controls and increased the lipolytic (fat-releasing) activity of adipose tissue, without impairing insulin sensitivity the way full-length GH can (Hormone Research 2000).
• In obese mice, two weeks of treatment reduced body weight and body fat and restored expression of the beta-3 adrenergic receptor — a fat-tissue receptor involved in energy expenditure. In mice engineered to lack that receptor, the chronic weight effect disappeared, pointing to a specific mechanism rather than a general toxic effect (Endocrinology 2001).

Note two details vendors rarely mention: the foundational rat study used oral dosing, not injections, and the doses were weight-based laboratory doses that do not translate directly to a human amount.

Metabolic Pharmaceuticals (Australia) took AOD-9604 into human obesity trials, with phase IIa studies underway by early 2002 (Current Opinion in Investigational Drugs 2004). The program then stalled: the company reported that its larger mid-stage obesity trial did not produce the hoped-for weight loss, and development for obesity was discontinued. Tellingly, no human efficacy trial of AOD-9604 was ever published in a peer-reviewed journal — a PubMed search returns animal studies, analytical-chemistry papers, and reviews, but no positive human weight-loss data. A 2026 sports-medicine review groups it with the "gray market" of unapproved peptides for which rigorous human data are scarce (Sports Medicine 2026).

AOD-9604's design goal was subtraction. Compared with full growth hormone, it is not reported to raise IGF-1, does not stimulate growth, and did not disturb glucose handling in the animal work above — the Zucker-rat study specifically found insulin sensitivity preserved under euglycemic-clamp testing. It is also not a GH secretagogue: unlike ipamorelin or GHRP-6, it does not make the pituitary release more of your own GH. That narrow profile was the selling point as a drug candidate, and it is also why the compound has no plausible muscle-building or "GH-like" recovery benefit.

After the obesity failure, the molecule resurfaced in preclinical joint research. In a rabbit model of collagenase-induced knee osteoarthritis, weekly intra-articular injections of AOD-9604 combined with hyaluronic acid produced less cartilage damage than either agent alone (Annals of Clinical Laboratory Science 2015). That is a single small animal study — interesting, but far from evidence for injecting AOD-9604 into human joints. For the current state of the literature, see the AOD-9604 research overview.